CCS
IPXL

Crosspoint Capital Strategies’s Impax Laboratories, Inc. IPXL Stock Holding History

Crosspoint Capital Strategies’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50
Closed -$2K – 1289
2015
Q3 		$2K Buy
+50
New +$2.25K ﹤0.01% 631

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Crosspoint Capital Strategies's IPXL Position: Q4 2015 in Review

Crosspoint Capital Strategies sold out of Impax Laboratories, Inc. (IPXL) in Q4 2015, closing a stake of 50 shares — an estimated $2K sold.

Crosspoint Capital Strategies first reported a position in IPXL in Q3 2015 and held it in 1 quarter. The position peaked at $2K in Q3 2015. 196 funds tracked by Wall St. Rank hold IPXL as of Q4 2015.

  • Crosspoint Capital Strategies reported no remaining Impax Laboratories, Inc. position as of Q4 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 50 Impax Laboratories, Inc. shares in Q4 2015, an estimated $2K.
  • Crosspoint Capital Strategies first reported a position in Impax Laboratories, Inc. in Q3 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Impax Laboratories, Inc. position peaked at $2K in Q3 2015.
  • 196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2015, filed 16 Feb 2016.